While we talk about Gland Pharma IPO, The organization headquartered in Hyderabad, Gland Pharma Ltd, is among the rapidly developing generic injectable firms. Gland Pharma Ltd, one of the fastest-growing generic injectable firms, is Hyderabad-based. It produces a sustainable set of different injectables of top standard.
The firm distributes drugs such as sterile, oncology & ophthalmic injectables, complicated injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, first-to-file items, respectively. it has 7 powerful processing plants consisting of 4 finished formulations, 22 production lines, and 3 APIs in India.
The corporation embraces a B2B structure to market its items in further than 60 nations, namely the us, Canada , Australia, India , Europe, respectively. Top firms in pharmaceutical, i.e. Apotex Inc., Sagent Pharmaceuticals, several of the main clients are Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc.
Credit – Raasta Studios
Table of Contents
Promoters of the Firm
Fosun Pharma Industrial Pte. Ltd & Shanghai Fosun Pharmaceutical Co. Ltd are promoters of the firm.
Promoters holding
- Pre Issue Share Holding- 74%
- Post Issue Share Holding – 58.3 %
Management
- Dr Ravi penmetsa (Mentor and Advisor)
- Mr. Srinivas sadu (MD & CEO),
- Mr. Kvgk Raju (CTO),
- Mr. Ravi shekhar mitra(CFO)
Financials Trends
| Items | For the year/period (All amounts are in Million) | ||||
|---|---|---|---|---|---|
| 30-Jun-20 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Gross Assets | 46,913 | 40,860 | 35,235 | 29,295 |
| Gross Income | 9,163 | 27,724 | 21,298 | 16,717 |
| Gross Expenses | 4963 | 1,7795 | 1,4235 | 1,1702 |
| Profit After Tax | 3136 | 7,729 | 4,519 | 3,211 |
| Net Margin (%) | 34 | 27 | 21 | 19 |
Gland Pharma IPO Summary
| IPO Date | 09 November, 2020 to 11 November, 2020 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 43,196,968 Equities of Rs.1 totaling up to Rs.6,480 Cr. |
| Fresh Issue | 8,333,333 Equities of Rs.1 totaling up to Rs. 1,250 Cr. |
| Offer for Sale | 34,863,635 Equities of Rs.1 totaling up to Rs.5,230 Cr. |
| Face Value | Rs.1 per equity stock |
| IPO Price | INR 1490 to Rs.1500 per equity stock |
| Market Lot | 10 Stocks |
| Min Order Quantity | 10 Stocks |
| Listing At | Bombay Stock Exchange, National Stock Exchange |
Basis of Allotment
| Type | % of Offer | Basis of Allotment |
|---|---|---|
| Qualified Institutional Buyer | Around 50% |
Roughly
equivalent
|
| Non Institutional Investor | Around 15% |
Roughly
equivalent
|
| Retail | Around 35% | Minimal level of 1 lot, based on availability, for every shareholder. |
Gland Pharma IPO‘s Tentative dates
| Bid/Offer start date | 09 November, 2020 |
| Bid/Offer end date | 11 November, 2020 |
| Allotment finalization date | 17 November, 2020 |
| Refunds starting from | 18 November, 2020 |
| Shares to be credited in Demat Account | 19 November, 2020 |
| Listing Date for IPO | 20 November, 2020 |
Purpose of the Gland Pharma IPO:
For the specified objectives, funds raised from the IPO would be utilised:
- Financing the firm’s additional working capital commitments
- Meeting the funding criteria for the standards for capital expenditure
- To achieve basic organisational goals
Gland Pharma IPO Proposal
Gland Pharma Official Contact Details
Gland Pharma Limited
Survey No. 143-148, 150 & 151
Near Gandimaisamma ‘X’ Roads
D.P. Pally, Dundigal Gandimaisamma Mandal
Medchal-Malkajgiri District
Hyderabad 500043, Telangana, India
Ph: +91 40 3051 0999, Fax: +91-40-30510800
Email ID: [email protected]
Web: http://www.glandpharma.com
Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park Lal Bahadur Shastri Marg, Vikhroli (West)
Mumbai – 400 083
Phone: +91 22 4918 6200
Fax: +91 22 4918 6195
Email: [email protected]
Website: http://www.linkintime.co.in
Gland Pharma IPO managers
- Citigroup Global Markets India Private Limited
- Haitong Securities India Private Limited
- Kotak Mahindra Capital Company Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
Positive Points for Gland Pharma IPO
- A comprehensive product selection of specific injectables.
- India ‘s diversified B2B structure with a focused B2c market.
- Good ability for growth.
- Reliable performance history financially.
- An established and qualified team of management.
Negative Points for Gland Pharma IPO
- ED had attached some shares of one promoter in a old ongoing legal issue.
- Margins are on very high levels.
Grey Market Premium
While we talk about Grey market Premium it is nearly 100% as of now. However, We will update you on daily basis till the time the IPO get listed.
Conclusion:
Throughout the last 3 years, Gland Pharma had good income performance. As among the country’s biggest pharma company most buyers wish to be a part of its company’s growth. Read and understand through the profitability of a business and the Red Herring Prospectus (RHP) thoroughly before investing. Please also a advise of your financial adviser before investing as they are many risk involve in share market.
We hope we are able to answer all you questions about In Gland Pharma IPO. If you don’t have Demat account open it now with Zerodha best trading app.
When Gland Pharma IPO will Open?
Gland Pharma IPO will Open on 9 November 2020 & it will close on 11 November 2020.
How can we apply for Gland Pharma IPO in Zerodha?
Open Kite(Zerodha's trading app) from there you can go to console and Click on Portfolio and checkout IPO option.
When Gland Pharma IPO will be Listed?
It will be get listed on 20 November 2020.
Who is Promoter of Gland Pharma?
Fosun Pharma is the main Promoter of Gland Pharma.
What is current GMP on Gland Pharma IPO?
Currently GMP is near 10%. However, It will change everyday till the time stock get listed.
